openPR Logo
Press release

Myelofibrosis Therapeutics Pipeline Analysis -Drug Profile, Top Industry Intelligence and Therapeutic Development

01-08-2018 09:22 PM CET | Health & Medicine

Press release from: P&S MARKET RESEARCH

Myelofibrosis Therapeutics Pipeline Analysis -Drug Profile,

The study analysed that the therapeutics pipeline comprises of approximately 29 drug candidates in different stages of development. Myelofibrosis is a rare disorder in which excessive scar tissue gets formed in the bone marrow that impairs its ability to produce red blood cells. However, it is believed by researchers that myelofibrosis occurs due to the presence of abnormal red blood stem cells in the bone marrow. The abnormal blood stem cells produce mature cells that grow quickly and form scar tissue which leads to chronic inflammation.
Access Detailed Report Summary at: https://www.psmarketresearch.com/market-analysis/myelofibrosis-therapeutics-pipeline-analysis

Various companies, educational institutes and medical organization are collaborating for the development of therapeutics for the treatment of myelofibrosis. For instance, Geron Corporation and Janssen Pharmaceuticals, Inc. entered into a collaboration agreement, in which Geron Corporation granted an exclusive worldwide right to Janssen, for the development and commercialization of imetelstat for all human therapeutic uses, including hematologic myeloid malignancies.

Download Report Sample at: https://www.psmarketresearch.com/market-analysis/myelofibrosis-therapeutics-pipeline-analysis/report-sample

According to the research, there are several companies having drug candidates in their pipeline, using synthetic sources for the development of drugs for the treatment of myelofibrosis. Imetelstat is an oligonucleotide obtained from synthetic source that acts as telomerase inhibitor.

Make Enquiry Before Buying the Report:
https://www.psmarketresearch.com/send-enquiry?enquiry-url=myelofibrosis-therapeutics-pipeline-analysis

Some of the key players developing drugs for myelofibrosis include CTI BioPharma Corporation, Geron Corporation, Gilead Sciences, Inc. and others.

Myelofibrosis Therapeutics Pipeline Analysis
• By Phase
• By Route of Administration
• By Molecule Type
• By Company

About P&S Market Research
P&S Market Research is a global market research and consulting company. We provide market research reports, industry reports, business intelligence and research based consulting services across a range of industries.

With the help of our professional corporate relations with various companies, our market research offers the most accurate market forecasting. Our analysts and consultants interact with leading companies of the concerned domain to substantiate every single data presented in our publication. Our research assists our client in identifying new and different windows of opportunity and frame informed and customized strategies for expansion in different regions.

Contact:
P&S Market Research
347, 5th Ave. #1402
New York City, NY - 10016
Toll-free: +1-888-778-7886 (USA/Canada)
Email: enquiry@psmarketresearch.com
Web: https://www.psmarketresearch.com

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Myelofibrosis Therapeutics Pipeline Analysis -Drug Profile, Top Industry Intelligence and Therapeutic Development here

News-ID: 890317 • Views:

More Releases from P&S MARKET RESEARCH

Smart Cities Market Size, Revenue, Technology, Competitive Analysis, Growth Drivers and Opportunities by 2023
Smart Cities Market Size, Revenue, Technology, Competitive Analysis, Growth Driv …
The global smart cities market is growing at a CAGR above 20% during 2018 - 2023 and will reach $2578.0 billion by 2023. Due to significant growth in automation technologies such as internet of things (IoT) and adoption of cloud based technologies, the global smart cities market is gaining huge traction. In addition, effective city asset management for public welfare, substantial operational cost savings, and automated public data generation applications
Global Sports Food Market Expected to Witness 9.2% CAGR During 2016 – 2022
Global Sports Food Market Expected to Witness 9.2% CAGR During 2016 – 2022
The global sports food market is expected to grow at a CAGR of 9.2% in terms of value during 2016 - 2022. Among the various types, the energy bars segment accounted for the largest share (71.5%) in the global sports food market in 2015. Request to Get the Sample Report@ https://www.psmarketresearch.com/market-analysis/sports-food-market/report-sample The manufacturers are trying to bring about products with the best blend of taste and healthy ingredients. They have started to
Sports Nutrition Market by Type, Distribution Channel, Region, Growth and Demand Forecast to 2022
Sports Nutrition Market by Type, Distribution Channel, Region, Growth and Demand …
The global sports nutrition market is expected to grow at a CAGR of 8.4% in terms of value during 2016 - 2022. Among the various types, the sports drinks segment accounted for largest share (61.4%) in the global sports nutrition market in 2015. Request to Get the Sample Report@ https://www.psmarketresearch.com/market-analysis/sports-nutrition-market/report-sample The increasing health concerns, such as obesity and awareness of physical appearances among all consumers groups is driving the demand for sports
Orthopedic Trauma Devices Market Supply Chain Trends Mapping the Latest Technological Advancements
Orthopedic Trauma Devices Market Supply Chain Trends Mapping the Latest Technolo …
The global orthopedic trauma devices market is growing due to the increasing frequency of fractures, along with the growth of aging population. The advantageous features posed by orthopedic trauma devices, such as internal and external fixators to set a fracture, and in repositioning of bone fragments into their normal alignment are also driving the growth of the market worldwide. Furthermore, the internal fixators have reduced the hospital stays, reduced the

All 5 Releases


More Releases for Myelofibrosis

Chronic Idiopathic Myelofibrosis Market 2022 | Detailed Report
The Chronic Idiopathic Myelofibrosis report understands the current and future competitive scenario across types, countries, and applications.It provides accurate, up-to-date analysis of markets and companies.The report use reliable information and analysis to gain a deeper understanding of the current factors impacting the industry. The Chronic Idiopathic Myelofibrosis report provides exact and accurate data that helps companies of all sizes to make timely decisions. Furthermore, the report provides robust solutions to customers,
Myelofibrosis Therapeutics Market Research Report by Valuates Reports
Latest updates on "Myelofibrosis Market" Primary myelofibrosis is a relatively rare bone marrow cancer. It is currently classified as a myeloproliferative neoplasm, in which the proliferation of an abnormal clone of hematopoietic stem cells in the bone marrow and other sites results in fibrosis, or the replacement of the marrow with scar tissue. The market report provides the overview of the Myelofibrosis by providing the disease overview, definition, classification, symptoms, etiology, pathophysiology
Post-Polycythemia Vera Myelofibrosis-Pipeline Review H2 2018
Publisher's latest Pharmaceutical and Healthcare disease pipeline guide Post-Polycythemia Vera Myelofibrosis (PPV-MF)-Pipeline Review, H2 2018, provides an overview of the Post-Polycythemia Vera Myelofibrosis (PPV-MF) (Oncology) pipeline landscape. Post-Polycythemia Vera Myelofibrosis (PPV-MF) is a myeloproliferative blood cancer in which the bone marrow makes too many red blood cells. It may also result in the overproduction of white blood cells and platelets. Symptoms include heart attack, stroke, deep venous thrombosis, Headaches, lack of
Myelofibrosis Treatment Market Opportunity Analysis, 2018-2026
Myelofibrosis is a bone marrow disease that interrupts the blood cells production process in the body. Fibrous or scar tissue gets developed in the bone marrow leading to scarring causing insufficient blood cell production. Myelofibrosis is a rare type of chronic leukemia affecting blood production. The symptoms of myelofibrosis include severe anemia, fatigue, weakness, and enlarged spleen. The disease is usually found to occur in individuals over the age of
Myelofibrosis Research and Development Pipeline Insight Report, 2017
Market Research Hub (MRH) has recently broadcasted a new study to its broad research portfolio, which is titled as “Myelofibrosis-Pipeline Insights, 2017” report provides comprehensive insights of the ongoing therapeutic research and development across Myelofibrosis. The report provides a complete understanding of the pipeline activities covering all clinical, pre-clinical and discovery stage products. A comparative pipeline therapeutics assessment of Myelofibrosis by development stage, therapy type, route of administration and molecule
Develop business Strategies Of Myelofibrosis Market 2025
"The Latest Research Report OpportunityAnalyzer: Myelofibrosis - Opportunity Analysis and Forecasts to 2025 provides information on pricing, market analysis, shares, forecast, and company profiles for key industry participants. - MarketResearchReports.biz" About Myelofibrosis Market Myelofibrosis (MF) is a rare blood disorder, which is characterized by bone marrow fibrosis. Currently, there is only one approved drug, Incyte/Novartis Jakafi (ruxolitinib), for the treatment of MF, and other conventional therapies used in MF are off-label. However,